Angiodynamics reports fiscal 2023 first quarter financial results; reaffirms guidance

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2023, which ended august 31, 2022. “we are pleased with our performance during the quarter as we continued to deliver on our long-term strategic objectives
ANGO Ratings Summary
ANGO Quant Ranking